Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

Analysis of data from a large patient population revealed a lower survival rate for men with prostate cancer (PCa) and depression compared with those without depression as well as healthy controls, ...

In prostate cancer, hormone therapy is treatment to keep the cancer cells from getting testosterone, the main male hormone (androgen). Hormone therapy for prostate cancer is also called ...

The novel MEK inhibitor atebimetinib in combination with modified gemcitabine/nab-paclitaxel led to a 12-month overall ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Dr. Matthew Smith answers the question: 'Hormone Refractory Prostate Cancer?' March 16, 2009 -- Question: What is hormone refractory prostate cancer? Answer: Nearly all men respond to initial ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

Joe Biden’s recent diagnosis of "aggressive" prostate cancer has sparked concerns about how far the disease has advanced. The former president’s prostate cancer has been characterized by a Gleason ...

A former prostate cancer patient who got the all-clear said taking part in a trial that cut his radiotherapy treatments ...